Date: 2015-01-13
Type of information: Nomination
Compound:
Company: UCB (Belgium)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 13, 2015, UCB announced that Jean-Christophe Tellier has taken up the role as CEO of UCB on 1 January 2015, succeeding Roch Doliveux. He is also Chairman of UCB’s Executive Committee and member of the Board of Directors. Roch Doliveux stepped down on 31 December 2014 after successfully leading UCB for the last 10 years. UCB’s Board of Directors granted him the titles of Honorary Member of the Board and Honorary Chairman of the Executive Committee. Jean-Christophe Tellier joined the company in 2011 and was instrumental in establishing the company’s current strategy; he has played a key role in driving the growth of UCB’s three core medicines, Cimzia®, Vimpat® and Neupro®.With a distinguished 25-year career in the biopharmaceutical industry, Jean Christophe Tellier comes with significant expertise and career achievements, a highly developed patient-focused approach, a medical background as a rheumatologist and a passion for developing talent. To fulfill the company’s mission Jean-Christophe Tellier will enjoy the support of a strong Executive Committee with new members joining the existing team. UCB’s leadership team, effective 1 February 2015, will have a clear focus on key disease or domain expertise areas. UCB's Executive Committee will be structured as follows, each unit being led by an Executive Vice President reporting to Jean-Christophe Tellier, Chief Executive Officer and Chairman of the Executive Committee. Patient Value Units: New Medicines : Ismail Kola, New Medicines Head and Chief Scientific Officer Patient Value Practices : Strategic Marketing : Bharat Tewarie, Chief Marketing Officer. A physician with strong industry experience, he joins UCB from Merck-Serono where he was Senior Vice President, head of Global Business Franchise Neurology & Immunology and head of Global Business Franchise Medical Devices Development and Medical: Iris Loew Friedrich, Chief Medical Officer Patient Value Operations: Geographic Operations, Established Brands, Technical Operations and Business Development: Mark McDade, Chief Operating Officer Patient Value Functions: Finance: Detlef Thielgen, Chief Financial Officer
Neurology : Jeff Wren, Patient Value Unit Head, previously head of UCB’s North American region
Immunology : Emmanuel Caeymaex, Patient Value Unit Head, previously head of UCB’s Cimzia® team
Bone disorders : this position is still to be filled and will be led ad interim by Iris Loew Friedrich
Talent and Company Reputation: Fabrice Enderlin, Chief Talent Officer
Legal: Anna Richo, General Counsel
Financial terms:
Latest news:
